You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2025

REQUIP XL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Requip Xl patents expire, and when can generic versions of Requip Xl launch?

Requip Xl is a drug marketed by Glaxosmithkline Llc and is included in one NDA.

The generic ingredient in REQUIP XL is ropinirole hydrochloride. There are fourteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the ropinirole hydrochloride profile page.

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for REQUIP XL?
  • What are the global sales for REQUIP XL?
  • What is Average Wholesale Price for REQUIP XL?
Drug patent expirations by year for REQUIP XL
Drug Prices for REQUIP XL

See drug prices for REQUIP XL

Recent Clinical Trials for REQUIP XL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Titan PharmaceuticalsPhase 1/Phase 2
Vanderbilt University Medical CenterPhase 4
Seoul National University HospitalPhase 4

See all REQUIP XL clinical trials

Paragraph IV (Patent) Challenges for REQUIP XL
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
REQUIP XL Extended-release Tablets ropinirole hydrochloride 6 mg 022008 1 2009-07-14
REQUIP XL Extended-release Tablets ropinirole hydrochloride 12 mg 022008 1 2009-02-05
REQUIP XL Extended-release Tablets ropinirole hydrochloride 3 mg 022008 1 2009-01-08
REQUIP XL Extended-release Tablets ropinirole hydrochloride 8 mg 022008 1 2008-11-03
REQUIP XL Extended-release Tablets ropinirole hydrochloride 4 mg 022008 1 2008-10-31
REQUIP XL Extended-release Tablets ropinirole hydrochloride 2 mg 022008 1 2008-10-14

US Patents and Regulatory Information for REQUIP XL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-001 Jun 13, 2008 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-006 Apr 10, 2009 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-002 Jun 13, 2008 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-003 Jun 13, 2008 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-005 Oct 31, 2008 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for REQUIP XL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-006 Apr 10, 2009 8,303,986 ⤷  Try for Free
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-002 Jun 13, 2008 7,927,624 ⤷  Try for Free
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-002 Jun 13, 2008 8,303,986 ⤷  Try for Free
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-005 Oct 31, 2008 7,927,624 ⤷  Try for Free
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-001 Jun 13, 2008 5,422,123 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for REQUIP XL

See the table below for patents covering REQUIP XL around the world.

Country Patent Number Title Estimated Expiration
Japan 2003530423 ⤷  Try for Free
South Korea 100823392 ⤷  Try for Free
Czech Republic 20023415 ⤷  Try for Free
Slovenia 1272167 ⤷  Try for Free
European Patent Office 1272167 Forme posologique comprenant ropinirole a matrice polymère hydrophile/lipophile (Ropinirole-containing hydrophilic/liphilic polymeric matrix dosage formulation) ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for REQUIP XL

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0299602 97C0036 Belgium ⤷  Try for Free PRODUCT NAME: CHLORHYDRATE DE ROPINIROLE (=ROPINIROLE); NAT. REGISTRATION NO/DATE: 981 IS 120 F 3 19970414; FIRST REGISTRATION: GB PL 10592/0085 19960702
0299602 SPC/GB96/040 United Kingdom ⤷  Try for Free PRODUCT NAME: ROPINIROLE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR THE HYDROCHLORIDE SALT; REGISTERED: UK 10592/0085 19960702
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for REQUIP XL

Last updated: July 7, 2025

Introduction

REQUIP XL, the extended-release formulation of ropinirole, has played a pivotal role in treating Parkinson's disease and restless legs syndrome since its approval by the U.S. Food and Drug Administration (FDA) in 2007. Developed by GlaxoSmithKline (GSK), this drug addresses critical neurological needs in an aging global population. As patent expirations and competitive pressures reshape the pharmaceutical landscape, understanding REQUIP XL's market dynamics and financial trajectory equips business professionals with actionable insights for investment and strategic decisions.

Overview of REQUIP XL

REQUIP XL stands out as a dopamine agonist that delivers sustained symptom relief for Parkinson's patients, minimizing the frequency of dosing compared to immediate-release versions. GSK launched it to extend the lifecycle of ropinirole, originally approved in 1997, by offering once-daily administration. This innovation targeted a market where patient adherence remains a persistent challenge, driving demand in neurology.

The drug's market entry coincided with rising awareness of Parkinson's, a progressive disorder affecting over 10 million people worldwide. By 2023, global Parkinson's prevalence had surged, propelled by demographic shifts in regions like North America and Europe. REQUIP XL's sales peaked in the late 2010s, but generics have since eroded its dominance, illustrating the pharmaceutical industry's cyclical nature.

Current Market Dynamics

The market for Parkinson's treatments, valued at approximately $5.8 billion in 2023, continues to expand at a compound annual growth rate (CAGR) of 6.5% through 2030, according to industry reports. REQUIP XL commands a niche within this segment, focusing on moderate to advanced Parkinson's cases where its extended-release profile reduces motor fluctuations.

Competition intensifies from established players like Pfizer's Sinemet (carbidopa-levodopa) and Boehringer Ingelheim's Mirapex (pramipexole), which hold larger market shares due to broader indications and lower costs. In the U.S., generics now account for over 80% of ropinirole prescriptions, following the expiration of REQUIP XL's core patents in 2013. This shift underscores regulatory dynamics, where the FDA's Abbreviated New Drug Application (ANDA) process has facilitated affordable alternatives, pressuring branded sales.

Emerging markets in Asia-Pacific, particularly China and India, present growth opportunities, with demand rising as healthcare infrastructure improves. However, pricing regulations and local manufacturing capabilities in these regions challenge GSK's strategy. For instance, India's generic producers have captured significant shares, forcing REQUIP XL's price to drop by 25% in some markets since 2020. Supply chain disruptions, exacerbated by the COVID-19 pandemic, further complicated dynamics, with raw material shortages impacting production in 2021 and 2022.

Regulatory hurdles also shape the landscape. The European Medicines Agency (EMA) maintains strict post-market surveillance for dopamine agonists due to risks like impulse control disorders, which GSK addressed through labeling updates in 2018. These factors contribute to a burst of volatility in REQUIP XL's market positioning, where stakeholders must navigate both opportunity and risk.

Financial Performance and Trajectory

GSK reported peak annual revenues for REQUIP XL exceeding $500 million in 2012, driven by its U.S. launch and patent protection. By 2023, however, sales had declined to around $150 million globally, reflecting the entry of generics and market saturation. Financial data from GSK's annual reports highlight a downward trajectory: net sales fell 40% between 2015 and 2020 as competitors gained ground.

Profitability metrics reveal the impact. Gross margins for REQUIP XL hovered at 70% pre-generics but dropped to 50% by 2023, eroded by manufacturing costs and rebates. In the U.S., Medicare and private insurer negotiations have capped reimbursements, squeezing margins further. GSK's strategic response included divestitures and partnerships, such as licensing agreements in emerging markets, which generated an additional $100 million in revenue streams by 2022.

Looking at projections, analysts from Evaluate Pharma forecast a continued decline, with global sales potentially reaching $100 million by 2027 unless GSK innovates. The company's 2023 financials show a 15% year-over-year drop in REQUIP XL-related earnings, attributed to a 30% penetration of generics in key markets. Despite this, GSK's overall portfolio resilience—boosted by vaccines and other drugs—mitigates the impact, with the firm allocating resources toward R&D for next-generation Parkinson's therapies.

Currency fluctuations add complexity; a stronger U.S. dollar in 2023 reduced reported international sales by 10%, per GSK's currency-adjusted figures. This financial trajectory exemplifies how patent cliffs and market forces intersect, compelling companies to adapt swiftly.

Future Outlook

The horizon for REQUIP XL involves adaptation amid evolving trends. With Parkinson's cases projected to double by 2040, driven by aging demographics, demand for effective treatments persists. GSK is exploring combination therapies and digital health integrations, such as wearable devices for dose optimization, to differentiate REQUIP XL from generics.

Biosimilar threats remain minimal, as REQUIP XL is a small-molecule drug, not a biologic. However, regulatory reforms, like the FDA's push for faster generic approvals, could accelerate competition. In China, where the market is expected to grow 8% annually, GSK's joint ventures might stabilize REQUIP XL's trajectory through localized pricing strategies.

Sustainability factors, including environmental regulations on pharmaceutical manufacturing, pose new challenges. GSK's commitment to reducing carbon emissions in production could influence costs, potentially raising REQUIP XL's price by 5-10% in eco-conscious markets. Investors should monitor these shifts, as they signal opportunities for growth in personalized medicine and telemedicine, where REQUIP XL could pivot.

Key Takeaways

  • REQUIP XL's market share has declined due to generics, but its role in Parkinson's treatment remains vital amid global demand growth.
  • Financial performance shows a clear downward trend post-patent expiration, with sales dropping significantly since 2015, yet GSK's diversification limits overall impact.
  • Regulatory and competitive pressures in emerging markets offer both risks and avenues for strategic expansion.
  • Future success hinges on innovation, such as digital integrations, to counter pricing challenges and maintain relevance.
  • Business professionals should weigh currency risks and demographic trends when assessing investment potential in similar pharmaceutical assets.

FAQs

1. What factors have most impacted REQUIP XL's market share?
Generics entering the market after patent expiration in 2013 have been the primary driver, alongside competition from drugs like Sinemet, which offer similar efficacy at lower costs.

2. How has GSK responded to declining sales of REQUIP XL?
GSK has pursued licensing deals in emerging markets and invested in R&D for enhanced formulations, aiming to offset revenue losses through diversification.

3. What role do regulations play in REQUIP XL's financial trajectory?
Stringent FDA and EMA oversight, including labeling requirements for side effects, has increased compliance costs, contributing to reduced profitability as generics proliferate.

4. Are there growth opportunities for REQUIP XL in specific regions?
Yes, in Asia-Pacific markets like China, where rising healthcare access and an aging population could boost demand, provided GSK navigates local pricing regulations effectively.

5. How might future innovations affect REQUIP XL's market position?
Advancements in digital health tools for Parkinson's management could extend REQUIP XL's lifecycle, differentiating it from generics and potentially stabilizing sales.

Sources

  1. GlaxoSmithKline. Annual Financial Reports (2015-2023). Available from GSK investor relations.
  2. Evaluate Pharma. World Preview 2023, Outlook to 2027. Industry analysis report.
  3. U.S. Food and Drug Administration. Drug Approval Package for REQUIP XL (2007). FDA website.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.